Zachary Pacheco, | |
1717 6th Ave S, Birmingham, AL 35233-1801 | |
(800) 822-8816 | |
Not Available |
Full Name | Zachary Pacheco |
---|---|
Gender | Male |
Speciality | Emergency Medicine |
Experience | 8 Years |
Location | 1717 6th Ave S, Birmingham, Alabama |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1285089482 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 36674 (Alabama) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Alabama Hospital | Birmingham, AL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Alabama Health Services Foundation, Pc | 1951213107 | 2344 |
News Archive
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
Published in the April issue of Journal of Nuclear Medicine, Gamma Medica, Inc. and Mayo Clinic of Rochester, MN document the achievement of a 5-fold reduction in the necessary dose of Tc-99m sestamibi to perform Molecular Breast Imaging (MBI). This achievement enables the new LumaGEM™ MBI System by Gamma Medica to deliver the same low radiation dose as digital screening mammography.
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
New research appearing online today in Clinical Chemistry, the journal of AACC, shows that decreased levels of vitamin D may predispose smokers to developing tobacco-related cancer.
Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology Research.
› Verified 3 days ago
Entity Name | University Of Alabama Health Services Foundation, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
Published in the April issue of Journal of Nuclear Medicine, Gamma Medica, Inc. and Mayo Clinic of Rochester, MN document the achievement of a 5-fold reduction in the necessary dose of Tc-99m sestamibi to perform Molecular Breast Imaging (MBI). This achievement enables the new LumaGEM™ MBI System by Gamma Medica to deliver the same low radiation dose as digital screening mammography.
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
New research appearing online today in Clinical Chemistry, the journal of AACC, shows that decreased levels of vitamin D may predispose smokers to developing tobacco-related cancer.
Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology Research.
› Verified 3 days ago
Entity Name | Paragon Contracting Services Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1225071459 PECOS PAC ID: 3971417825 Enrollment ID: O20050218000756 |
News Archive
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
Published in the April issue of Journal of Nuclear Medicine, Gamma Medica, Inc. and Mayo Clinic of Rochester, MN document the achievement of a 5-fold reduction in the necessary dose of Tc-99m sestamibi to perform Molecular Breast Imaging (MBI). This achievement enables the new LumaGEM™ MBI System by Gamma Medica to deliver the same low radiation dose as digital screening mammography.
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
New research appearing online today in Clinical Chemistry, the journal of AACC, shows that decreased levels of vitamin D may predispose smokers to developing tobacco-related cancer.
Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology Research.
› Verified 3 days ago
Entity Name | Trinity Emergency Physicians, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1487669016 PECOS PAC ID: 7911909973 Enrollment ID: O20070205000660 |
News Archive
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
Published in the April issue of Journal of Nuclear Medicine, Gamma Medica, Inc. and Mayo Clinic of Rochester, MN document the achievement of a 5-fold reduction in the necessary dose of Tc-99m sestamibi to perform Molecular Breast Imaging (MBI). This achievement enables the new LumaGEM™ MBI System by Gamma Medica to deliver the same low radiation dose as digital screening mammography.
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
New research appearing online today in Clinical Chemistry, the journal of AACC, shows that decreased levels of vitamin D may predispose smokers to developing tobacco-related cancer.
Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology Research.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Zachary Pacheco, 1717 6th Ave S, Birmingham, AL 35233-1801 Ph: () - | Zachary Pacheco, 1717 6th Ave S, Birmingham, AL 35233-1801 Ph: (800) 822-8816 |
News Archive
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
Published in the April issue of Journal of Nuclear Medicine, Gamma Medica, Inc. and Mayo Clinic of Rochester, MN document the achievement of a 5-fold reduction in the necessary dose of Tc-99m sestamibi to perform Molecular Breast Imaging (MBI). This achievement enables the new LumaGEM™ MBI System by Gamma Medica to deliver the same low radiation dose as digital screening mammography.
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
New research appearing online today in Clinical Chemistry, the journal of AACC, shows that decreased levels of vitamin D may predispose smokers to developing tobacco-related cancer.
Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology Research.
› Verified 3 days ago
Janyce M Sanford, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1806 Sixth Avenue South, Birmingham, AL 35249 Phone: 205-975-7389 Fax: 205-975-4662 | |
Dr. Elizabeth Holcombe Adams, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 218 Devon Dr, Birmingham, AL 35209 Phone: 662-368-8602 | |
Dr. Melissa Leigh Peters, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1600 7th Ave S, Birmingham, AL 35233 Phone: 205-638-9587 Fax: 205-975-4623 | |
Alan Frederick Kitchens, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 50 Medical Park Dr E, St. Vincent's East, Birmingham, AL 35235 Phone: 205-545-9530 Fax: 205-545-9529 | |
John Gullett, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-5038 | |
Dr. Edward Payson Daugherty, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 151 Narrows Pkwy, Suite 110, Birmingham, AL 35242 Phone: 205-444-9550 Fax: 205-314-3360 | |
Mary H Maddox, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1600 7th Ave S, Birmingham, AL 35233 Phone: 205-939-9587 Fax: 205-975-4623 |